Utilization of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

Autologous stem cell transplant (ASCT) is a standard of care treatment for eligible patients with multiple myeloma (MM).1 Patients typically receive induction therapy with chemotherapy regimens consisting of immunomodulatory agents, proteasome inhibitors, and anti-CD38 monoclonal antibodies.1,2 Consolidative ASCT after induction therapy has been shown to improve progression free survival,1,3 with some studies also showing an overall survival (OS) benefit.4 –11 Most institutional and consensus guidelines recommend that at time of first ASCT, enough hematopoietic stem cells (HSC) should be collected to perform two stem cell transplants, with a minimum goal of 2 million CD34+ cells/kg.

Source: Biology of Blood and Marrow Transplantation - February 25, 2021 Category: Hematology Authors: Emily C. Liang, Lori S. Muffly, Parveen Shiraz, Judith A. Shizuru, Laura Johnston, Sally Arai, Matthew J. Frank, Wen-Kai Weng, Robert Lowsky, Andrew Rezvani, Everett H. Meyer, Robert Negrin, David B. Miklos, Surbhi Sidana Source Type: research